SF
Therapeutic Areas
Ottimo Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OTP-01 (Jankistomig) | Cancers known to benefit from PD-1 and/or VEGF treatment (e.g., solid tumors) | Phase 1/2a |
Leadership Team at Ottimo Pharma
DE
David Epstein
Chair & Chief Executive Officer
MS
Mehdi Shahidi
Head of Development & Chief Medical Officer
LZ
Ling Zeng
General Counsel and EVP of Execution
JF
Jonny Finlay
Founder and Chief Scientific Advisor
RA
Rick Anderson
SVP Finance
RT
Robert Tighe
SVP Preclinical and Translational Sciences
RD
Roger Dansey
Board Director